TTTech Delivers Distributed IMA Test Bed with TTEthernet to Sikorsky Aircraft

VIENNA, Austria–(Business Wire)–
TTTech, the leading supplier of dependable networking solutions based on
time-triggered technology, has delivered a Distributed Integrated Modular
Avionics (IMA) test bed to Sikorsky Aircraft Corporation, a subsidiary of United
Technologies Corp. (NYSE:UTX). Distributed IMA is a class of integrated
architectures which inherits all benefits of Integrated Modular Avionics based
upon the ARINC 653 avionics standard, and enables the efficient design of
distributed systems with mixed criticality applications. Distributed IMA based
on the TTEthernet protocol can significantly control system complexity while
facilitating designs of advanced and reliable electronic systems with lower life
cycle costs.

Sikorsky Aircraft is working on a proof-of-concept for the new generation of
modular, reusable, and scalable integrated vehicle management system. In
contrast to existing IMA systems, hard real-time control loops and isochronous
audio and video can reside in the same network with other critical and
non-critical functions and operating systems.

For the integration of hosted functions on different end systems, Sikorsky has
selected TTEthernet (SAE AS6802 Time-Triggered Ethernet) as a deterministic,
high-speed, fault-tolerant 1 Gbit/s backbone network.

“This type of distributed IMA eliminates conflicts in flexible integration of
critical and non-critical functions in distributed systems,” said Bill Kinahan,
Software Systems Technical Fellow of Sikorsky Aircraft. “The technology does not
impose constraints on distribution or centralization of functions, and therefore
we can do what is necessary to optimize our integrated systems.”

“Time-triggered technologies enable design of mixed criticality distributed
systems and platforms for next generation avionics using COTS components today,”
says Kurt Doppelbauer, Vice President Sales and Chief Sales Officer of TTTech
North America. “We are pleased with the opportunity to support advanced system
architectures at Sikorsky Aircraft by providing first-class products and
integration with leading open and industry standards.”

TTEthernet provides a set of time-triggered services implemented on top of
standard IEEE 802.3 Ethernet. Those services are designed to enable design of
synchronous, highly dependable embedded computing and networking, capable of
tolerating multiple faults. With TTEthernet, robustly partitioned multimedia
data streams, critical control data and standard LAN messages can operate in one
network without congestion or unintended interactions.

TTTech Computertechnik AG
Petra Platzer
Tel: +43 1 585 34 34-899
Fax: +43 1 585 34 34-90
E-mail: pr@tttech.com

Copyright Business Wire 2010

Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression

HAMBURG, Germany, July 1, 2010 (GLOBE NEWSWIRE) — Evotec AG (Frankfurt:EVT)
(TecDAX) today announced the start of the proof-of-concept Phase II study in
treatment-resistant depression with its NR2B subtype selective NMDA receptor
antagonist EVT 101. This clinical development is part of an alliance between
Evotec and Roche (SIX:RO) (SIX:ROG) (OTCQX:RHHBY).

The proof-of-concept Phase II study with EVT 101, which is being conducted in
the United States, has the main objective of studying the safety and
tolerability of EVT 101 while also exploring the efficacy of this intervention.
Approximately 100 patients suffering from treatment-resistant depression will
participate in it. Treatment-resistance of patients will be confirmed in a
6-week prospective antidepressant treatment phase preceding the actual 4-week
double-blind treatment.

Treatment-resistance to antidepressant drugs is observed in up to 30% of
depressed patients. NMDA receptor antagonists represent an alternative mechanism
that has the potential to improve depression in patients resistant to
conventional antidepressants.

Dr Werner Lanthaler, Chief Executive Officer of Evotec AG, commented: “The
clinical development of EVT 101 is addressing an area of significant unmet
medical need, and this development represents a big market opportunity. We are
happy to have Roche, as a recognised pioneer for novel solutions in the CNS
area, for this development with us.”

ABOUT NMDA RECEPTORS IN TREATMENT-RESISTANT DEPRESSION

NMDA receptors are involved in the pathology of depression. NR2B-selective
antagonists bind preferentially to the activated form of the NMDA receptor
containing the NR2B subunit and allosterically modulate, in an
activity-dependent manner, channel activity by inhibiting channel opening
probability. They show advantages over non-selective NMDA antagonists due to
greater separation of efficacy from side effects. The non-selective NMDA
receptor blocker ketamine and an NR2B-selective NMDA antagonist have shown in
exploratory clinical trials the potential to provide clinical benefit for
patients with treatment-resistant depression. However, both molecules, for which
proof of concept has been shown before, require parenteral administration, hence
an orally active therapeutic option is needed. EVT 101 is an orally available
compound which is well tolerated at dose levels considered to reach CNS levels
which go along a high NMDA receptor occupancy. In a Phase I fMRI study performed
with EVT 101 pharmacodynamic effects were seen at exposures similar to those
planned for the ongoing proof of concept study.

ABOUT EVOTEC & ROCHE ALLIANCE

Evotec has entered an alliance with Roche for Phase II clinical development of
EVT 101 in patients with treatment-resistant depression. The potential value of
this transaction exceeds USD 300 million. Evotec is responsible for conducting
Phase II studies for EVT 101, a compound originally discovered by Roche and
developed from discovery stages through clinical studies by Evotec. Within this
alliance, Evotec has conducted the first Phase I safety and tolerability study
for EVT 103, a next generation compound to EVT 101. Roche fully funds these
development programmes.

ABOUT EVOTEC AG

Evotec is a leader in the discovery and development of novel small molecule
drugs with operational sites in Europe and Asia. The Company has built
substantial drug discovery expertise and an industrialised platform that can
drive new innovative small molecule compounds into the clinic. In addition,
Evotec has built a deep internal knowledge base in the treatment of diseases
related to neuroscience, pain, oncology and inflammation. Leveraging these
skills and expertise the Company intends to develop best-in-class differentiated
therapeutics and deliver superior science-driven discovery alliances with
pharmaceutical and biotechnology companies. Evotec has long-term discovery
alliances with partners including Boehringer Ingelheim, CHDI, Genentech,
Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in
clinical development and a series of preclinical compounds and development
partnerships, including for example a strategic alliance with Roche for the EVT
100 compound family, subtype selective NMDA receptor antagonists for use in
treatment-resistant depression. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. Such forward-looking statements include, but are not limited to,
statements about our 2010 financial outlook and our expected financial results
in future quarters, our ability to deliver on our liquidity guidance, our belief
that we are on course to profitability in 2012, our expectations and assumptions
concerning regulatory, clinical and business strategies, the progress of our
clinical development programmes and timing of the commencement and results of
our clinical trials, strategic collaborations and management’s plans, objectives
and strategies. These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the risks and
uncertainties include, among other things; risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured; the risk
that we will not achieve the anticipated benefits of our collaborations,
partnerships and acquisitions in the timeframes expected, or at all; risks
relating to our ability to advance the development of product candidates
currently in the pipeline or in clinical trials; our inability to further
identify, develop and achieve commercial success for new products and
technologies; the risk that competing products may be more successful; our
inability to interest potential partners in our technologies and products; our
inability to achieve commercial success for our products and technologies; our
inability to protect our intellectual property and the cost of enforcing or
defending our intellectual property rights; our failure to comply with
regulations relating to our products and product candidates, including FDA
requirements; the risk that the FDA may interpret the results of our studies
differently than we have; the risk that clinical trials may not result in
marketable products; the risk that we may be unable to successfully secure
regulatory approval of and market our drug candidates; and risks of new,
changing and competitive technologies and regulations in the U.S. and
internationally.

The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.

CONTACT: Evotec AG
Dr Werner Lanthaler, Chief Executive Officer
+49.(0)40.56081-242
werner.lanthaler@evotec.com

Evotec AG: Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression

Evotec AG / Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression
processed and transmitted by Hugin AS. The issuer is solely responsible for the content
of this announcement.

Hamburg, Germany – 1 July2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today
announced the start of the proof-of-concept Phase II study in treatment-resistant
depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This
clinical development is part of an alliance between Evotec and Roche (SIX: RO, ROG;
OTCQX: RHHBY).

The proof-of-concept Phase II study with EVT 101, which is being conducted in the United
States, has the main objective of studying the safety and tolerability of EVT 101 while
also exploring the efficacy of this intervention. Approximately 100 patients suffering
from treatment-resistant depression will participate in it. Treatment-resistance of
patients will be confirmed in a 6-week prospective antidepressant treatment phase
preceding the actual 4-week double-blind treatment.

Treatment-resistance to antidepressant drugs is observed in up to 30% of depressed
patients. NMDA receptor antagonists represent an alternative mechanism that has the
potential to improve depression in patients resistant to conventional antidepressants.

Dr Werner Lanthaler, Chief Executive Officer of Evotec AG, commented: “The clinical
development of EVT 101 is addressing an area of significant unmet medical need, and this
development represents a big market opportunity. We are happy to have Roche, as a
recognised pioneer for novel solutions in the CNS area, for this development with us.”

About NMDA receptors in treatment-resistant depression
NMDA receptors are involved in the pathology of depression. NR2B-selective antagonists
bind preferentially to the activated form of the NMDA receptor containing the NR2B
subunit and allosterically modulate, in an activity-dependent manner, channel activity
by inhibiting channel opening probability. They show advantages over non-selective NMDA
antagonists due to greater separation of efficacy from side effects. The non-selective
NMDA receptor blocker ketamine and an NR2B-selective NMDA antagonist have shown in
exploratory clinical trials the potential to provide clinical benefit for patients with
treatment-resistant depression. However, both molecules, for which proof of concept has
been shown before, require parenteral administration, hence an orally active therapeutic
option is needed. EVT 101 is an orally available compound which is well tolerated at
dose levels considered to reach CNS levels which go along a high NMDA receptor
occupancy. In a Phase I fMRI study performed with EVT 101 pharmacodynamic effects were
seen at exposures similar to those planned for the ongoing proof of concept study.

About Evotec & Roche Alliance
Evotec has entered an alliance with Roche for Phase II clinical development of EVT 101
in patients with treatment-resistant depression. The potential value of this transaction
exceeds USD 300 million. Evotec is responsible for conducting Phase II studies for EVT
101, a compound originally discovered by Roche and developed from discovery stages
through clinical studies by Evotec. Within this alliance, Evotec has conducted the first
Phase I safety and tolerability study for EVT 103, a next generation compound to EVT
101. Roche fully funds these development programmes.

Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler@evotec.com
mailto:werner.lanthaler@evotec.com

FORWARD LOOKING STATEMENTS – Information set forth in this press release contains
forward-looking statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to, statements about our 2010
financial outlook and our expected financial results in future quarters, our ability to
deliver on our liquidity guidance, our belief that we are on course to profitability in
2012, our expectations and assumptions concerning regulatory, clinical and business
strategies, the progress of our clinical development programmes and timing of the
commencement and results of our clinical trials, strategic collaborations and
management’s plans, objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties, many of which are
beyond our control, and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the risks and
uncertainties include, among other things; risks that product candidates may fail in the
clinic or may not be successfully marketed or manufactured; the risk that we will not
achieve the anticipated benefits of our collaborations, partnerships and acquisitions in
the timeframes expected, or at all; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in clinical trials; our
inability to further identify, develop and achieve commercial success for new products
and technologies; the risk that competing products may be more successful; our inability
to interest potential partners in our technologies and products; our inability to
achieve commercial success for our products and technologies; our inability to protect
our intellectual property and the cost of enforcing or defending our intellectual
property rights; our failure to comply with regulations relating to our products and
product candidates, including FDA requirements; the risk that the FDA may interpret the
results of our studies differently than we have; the risk that clinical trials may not
result in marketable products; the risk that we may be unable to successfully secure
regulatory approval of and market our drug candidates; and risks of new, changing and
competitive technologies and regulations in the U.S. and internationally.
The list of risks above is not exhaustive. Our most recent Annual Report on Form 20-F,
filed with the Securities and Exchange Commission, and other documents filed with, or
furnished to the Securities and Exchange Commission, contain additional factors that
could impact our businesses and financial performance. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.

HUG#1428277

Pdf of PressRelease http://hugin.info/131215/R/1428277/376190.pdf

— End of Message —

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

OXiGENE Presents Encouraging Preclinical Data on ZYBRESTAT Ophthalmology Program

SOUTH SAN FRANCISCO, Calif., June 22, 2010 (GLOBE NEWSWIRE) — OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, announced today that the company
presented an update on its ZYBRESTAT ophthalmology program, including
encouraging preclinical data showing that the company’s topical formulation
achieved target retina/choroid concentrations with minimal systemic exposure.
OXiGENE has two topical formulations of ZYBRESTAT in development — an eye drop
and a minitab — both of which have demonstrated attractive pharmacokinetic and
safety properties and efficacy in destroying abnormal vasculature in a rat
choroidal melanoma model. The company believes that a topical formulation could
be ready for clinical development in early 2011.

The data were presented at Glaucoma and Retinopathies 2010 conference by Dai
Chaplin, Ph.D., head of research and development and chief scientific officer at
OXiGENE.

“We are pleased with the outcome of preclinical studies with our topical
formulations and believe that ZYBRESTAT has significant potential as a safe,
effective, potent topical product that can improve upon injectable
anti-angiogenic agents which are the mainstay of treatment for conditions such
as age-related macular degeneration, but which may have limited efficacy and
inconvenient means of delivery,” said Dr. Chaplin. “We believe that our
ZYBRESTAT ophthalmology program is achieving critical mass in demonstrating
significant therapeutic and commercial potential. We look forward to presenting
our data package to companies with strong ophthalmology franchises with the goal
of partnering this promising program.”

OXiGENE has previously reported positive results from proof-of-concept Phase 2
studies using an intravenous formulation showing that ZYBRESTAT achieved the
primary endpoint of stable disease in patients with myopic macular degeneration
(MMD). The ongoing FAVOR (fosbretabulin against vasculopathy of the
retina/choroid) is a 20-patient, randomized, controlled, double-masked
single-dose study of intravenous-route ZYBRESTAT in patients with polypoidal
choroidal vasculopathy or PCV, a form of choroidal neovascularization that can
serve as a model disease for macular degeneration. Data from the FAVOR study is
intended to facilitate dose selection decisions in subsequent studies with
topical-route ZYBRESTAT.

Dr. Chaplin added: “We believe PCV represents an attractive development pathway,
as anti-angiogenic drugs are not approved for this indication and have not been
reported to have strong activity. Because the phenotype of pathological
vasculature in patients with PCV is similar to that of tumor vasculature, PCV is
likely to be particularly susceptible to treatment with a vascular disrupting
agent, such as ZYBRESTAT. We expect to report data from the FAVOR study later in
2010.”

About ZYBRESTAT (fosbretabulin)

ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-small cell
lung cancer and other clinical trials, including the FAVOR study in patients
with PCV. OXiGENE believes that ZYBRESTAT is poised to become an important
product in a novel class of small-molecule drug candidates called vascular
disrupting agents (VDAs). Through interaction with vascular endothelial cell
cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor
vasculature, thereby depriving the tumor of oxygen and causing death of tumor
cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and
selective activity against tumor vasculature, as well as clinical activity
against ATC, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The Company’s major focus is
developing vascular disrupting agents that selectively disrupt abnormal blood
vessels associated with solid tumor progression and visual impairment. OXiGENE
is dedicated to leveraging its intellectual property and therapeutic development
expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at

http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

This news release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release, which include projected study
and topical formulation timelines and outcomes, therapeutic and commercial
potential and the potential of partnering ZYBRESTAT ophthalmology programs may
turn out to be wrong. Forward-looking statements can be affected by inaccurate
assumptions OXiGENE might make or by known or unknown risks and uncertainties,
including, but not limited to continued financing for the continuation of
development efforts, the potential for negative clinical study or formulation
development outcomes, a lack of superior competitive results and the absence of
third party interest in jointly developing ZYBRESTAT. Additional information
concerning factors that could cause actual results to materially differ from
those in the forward-looking statements is contained in OXiGENE’s reports to the
Securities and Exchange Commission, including OXiGENE’s reports on Form 10-K,
10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future events or
otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year
ended December 31, 2009.

CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
medwards@oxigene.com

Research and Markets: Select the Right Vendor for Server Virtualization

DUBLIN–(Business Wire)–
Research and Markets
(http://www.researchandmarkets.com/research/2e1511/select_the_right_v) has
announced the addition of the “Select the Right Vendor for Server
Virtualization” report to their offering.

VMware continues to dominate but Citrix and now Microsoft offer viable
alternatives.

Your Challenge

* Situation. For serious server virtualization beyond proof of concept testing
VMware is the obvious choice, as it dominates the market. Many organizations do
not explore alternatives.
* Limitation. While VMware leads in features, functions and market share, it is
also a proprietary approach and the most expensive. Citrix XenServer has rapidly
closed the features gap and Microsoft is close behind with Hyper-V R2. Both are
cheaper and function in a heterogeneous (multi-hypervisor) environment.
* Solution. VMware will likely top the short list but it is now possible to
actually have a short list. For lower costs considerations Citrix XenServer and
Microsoft Hyper-V R2 are viable alternatives.

Our Advice

Critical Insight

VMware’s significant market share shouldn’t be a deciding factor. Consider the
strengths and weaknesses of all of the vendors:

* Citrix’s free management tools vs. battling the mindset that Citrix = desktop
virtualization
* Microsoft’s quickly maturing Hyper-V vs. out of touch licensing scheme

Impact and Result

* Virtualization first-timers should start with free hypervisors to achieve
basic server partitioning and consolidation and to gain experience with
virtualization.
* Management tools come at a price but are needed to take virtualization efforts
to a higher level (e.g., disaster recovery goals).
* Vendors eventually want to lead enterprises up the path to the cloud; server
virtualization is a key enabler of cloud initiatives.

What you receive:

Key Topics Covered:

* What Citrix XenServer Adds to Xen Virtualization (Pdf)
* Hyper-V R2: Microsoft Fills its Virtualization Gaps (Pdf)
* VMware vSphere: Next Step in Virtualization (Pdf)
* XenServer 5.5: Keeping Up with Citrix’s Latest Update (Pdf)
* VMware Go: Adds Value to ESXi Hypervisor (Video)
* Battle of the Hypervisors: How Do They Compare? (Pdf)
* ESXi: No-Charge Hypervisors Boost Consolidation Savings (Pdf)
* How the Free XenServer Ups the Management Ante (Pdf)
* VMware Highlights Memory as a Differentiator (Pdf)
* Vendor Landscape: Competitors Catch Up to VMware (Pdf)
* Oracle Consolidates Xen Based Virtualization Players (Pdf)

For more information visit

http://www.researchandmarkets.com/research/2e1511/select_the_right_v

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010

Study Shows Marked Neuroprotective Effects of Oxycyte(R) Perfluorocarbon Emulsion…

Study Shows Marked Neuroprotective Effects of Oxycyte(R) Perfluorocarbon
Emulsion in a Rat Model of Spinal Cord Injury

DURHAM, N.C., June 3, 2010 (GLOBE NEWSWIRE) — Oxygen Biotherapeutics, Inc.
(Nasdaq:OXBT) today reported on the results of two University of Miami Miller
School of Medicine studies involving the Company’s third-generation
perfluorocarbon, Oxycyte(R) perfluorocarbon emulsion. Both study reports showed
that Oxycyte(R) has a marked neuroprotective effect in a rat model of spinal
cord injury.

“Having proof-of-concept is a first step toward moving Oxycyte down the spinal
cord injury track. The positive results observed in both studies may warrant
efforts to pursue partnerships to conduct clinical studies of Oxycyte in spinal
cord injury in the future,” said Gerald Klein, Chief Medical Officer for Oxygen
Biotherapeutics.

The studies showed that histologically, Oxycyte improves the volume of preserved
neuronal tissue in the spinal cord following injury; a favorable improvement in
functional recovery, as assessed by footprint analysis six weeks post treatment,
has also been observed.

The study entitled “Possible Role of Hyperbaric Oxygen Therapy (HBO) and Oxycyte
After Spinal Cord Injury in Rats,” will be part of the poster sessions at the
National Neurotrauma Symposium on June 14-16, 2010 at the Paris Hotel in Las
Vegas. Results of the first study entitled “Evaluation of the Neuroprotective
and Behavioral Effects of the Perfluorocarbon Oxycyte After Spinal Cord Injury
(SCI) in the Rat” were presented in September 2009 at the annual
National-International Neurotrauma Symposium by Dr. Ross Bullock, University of
Miami Miller School of Medicine. Both studies received funding from Oxygen
Biotherapeutics.

Oxycyte emulsion is a proprietary therapeutic oxygen carrier. It is a
perfluorocarbon emulsified with water and a surfactant that is delivered
intravenously.

According to statistics from various studies compiled by the National Spinal
Cord Injury Statistical Center in Birmingham, AL, an estimated 12,000 new cases
of spinal cord injury occur each year in the United States; and the number of
people living in the United States with SCI is estimated to be approximately
259,000 people.

About the Company

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that
efficiently deliver oxygen to tissues in the body. The company has developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid
ventilation product called Oxycyte(R) that is being formulated for both
intravenous and topical delivery. In April, the company launched its first
cosmetic product, Dermacyte(R) Oxygen Concentrate. In addition, the company is
focused on perfluorocarbon-based oxygen carriers for use in traumatic brain
injury, decompression sickness, personal care, and topical wound healing. More
information is available at www.oxybiomed.com or www.buydermacyte.com.

The Oxygen Biotherapeutics, Inc. logo is available at

http://www.globenewswire.com/newsroom/prs/?pkgid=7277

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company’s judgment as of
the date of this release. These statements include those referring to the plans
for the expansion of development of the Oxycyte product line and the timing of
the introduction of those new products. The forward looking statements are
subject to a number of risks and uncertainties including matters beyond the
company’s control that could lead to delays in the new product introductions and
customer acceptance of these new products and other risks and uncertainties as
described in our filings with the Securities and Exchange Commission, including
in the current report on Form 8-K on May 4, 2010. Furthermore, there can be no
assurance that such plans will lead to meaningful sales of Dermacyte or generate
any revenue for the company. The company disclaims any intent or obligation to
update these forward-looking statements beyond the date of this release. This
caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.

CONTACT: Oxygen Biotherapeutics, Inc.
Ellen Corliss, Vice President, Corporate Communications
& Investor Relations
(919) 806-4405

Draft bill on UIDAI to be ready within a month: Nandan Nilekani

New Delhi, May 12 (ANI): Unique Identification Authority of India (UIDAI) chairman Nandan Nilekani has said the draft bill on the Unique Identity Project would be made ready for public discussion within a month”s time.

Talking to reporters on the sidelines of a function here on Tuesday, Nilekani said: “We need a UIDAI Act to govern the regulatory bodies; for that purpose we are drafting something, which we will put out in the next three to four weeks for public discussion.”
“The project would address issues of multiple identities and thereby plug leakages in various welfare schemes mooted by the government, he added.

“Right now we are doing proof of concept in Andhra Pradesh, Karnataka and Bihar. Then starting some pilot roll out in next few months and we have told earlier we will have UID roll out between August of this year and February of next year. We intend to stick on to these dates,” he said.

The Unique Identification Project has two aspects – one to provide a unique identification number to all Indians and second to provide online authentication.

Once the unique identification number starts to be accepted as an identity proof, it will benefit millions of poor Indians without any identification, access public services.

The identification would be biometrics based and the database would be a private database which could be used only for authentication.

The first set of identifications is expected to be rolled out by February 2011 and around 600 million Indians would be enrolled over the next four years. (ANI)

Dassault Systemes and IBM Expand Global Alliance

Recently Signed Alliance Accelerates Innovation with Global Financing, Cloud
Computing, Combined Industry Solutions and Services
LAS VEGAS–(Business Wire)–
Dassault Systèmes (DS)(Paris:DSY)(Euronext Paris: #13065, DSY.PA), a world
leader in 3D and Product Lifecycle Management (PLM) solutions, and IBM (NYSE:
IBM) today announced an expansion of their long-standing partnership and
highlighted at IBM`s IMPACT 2010 event the early deliverables of their Global
Alliance, including financing solutions from IBM Global Financing, a joint
competency center, and work on a PLM cloud computing proof of concept.

“Bentley has a long-term relationship with Dassault Systèmes and IBM built up
around software, systems and services. This relationship has helped us
accelerate and improve our Engineering Design and Manufacturing PLM processes as
we developed the Bentley Mulsanne, moving it through to the start of production
in 2010,” said John Unsworth, CAD strategy manager, Bentley Motors Limited.
“Integration, teaming and access to industry best practices have been critical
to our success with knowledge and skills transfer leading us closer to self
sufficiency. Bentley strives for continuous improvement throughout all of its
activities and we are always keen to exploit the next level of process
concurrency. Dassault Systèmes and IBM solutions and best practices will be a
factor in helping us get there.”

The two companies, which represent the PLM industry`s longest running alliance,
continue to invest in developing, deploying and supporting client PLM
environments. Further results from the alliance signed last month include a DS
PLM V6 software cloud computing technical proof of concept presented at the IBM
IMPACT 2010 conference this week. The concept illustrates how clients can take
advantage of DS software via a range of delivery options, from on-premise
solutions, to a cloud powered by IBM software, hardware and services that can
help reduce IT complexity and minimize operational costs.

This latest expansion includes a dedicated team of IBM and DS personnel focused
on enabling, marketing, and delivering PLM solutions necessary for clients to
transform their business. To this end, the companies established an
industry-first joint PLM competency center focused on optimizing DS PLM V6
solutions for performance, reliability, and scalability on an IBM
infrastructure.

“Our global alliance is focused directly on our customers` success. It covers
flexible financing options, PLM-on-the-cloud, combined infrastructure, software
and services solutions, as well as a one-of-a-kind competency center for
industrialization of V6 solutions on IBM infrastructure,” said Philippe
Forestier, executive vice president, Global Affairs, Dassault Systèmes. “These
are all a means to a single end: our customers` innovation and business
transformation strategies. Strategies such as these are significant and our
customers deserve the best solutions and services in the industry to ensure a
successful implementation and genuine return on investment.”

The IBM Global Financing portfolio is designed to help fuel innovation for
clients using the combination of DS and IBM technology, providing payment
options that meet their budget, return on investment and project payback
criteria. From simple loans to custom leases and terms as long as 60 months, IBM
can finance the total PLM solution – including hardware, software and services -
by providing affordable monthly rates and flexible payment structures.

IBM and DS`s collaboration pre-dates the PLM industry, as the two companies
collaborated first in 1981 and later jointly created and marketed the concept of
Product Lifecycle Management. DS’s PLM solutions leverage IBM WebSphere, Tivoli,
Information Management, Lotus and Rational software and IBM systems to provide
clients with a 3D vision of the entire lifecycle of their products. The combined
solutions help clients to develop products from conception to maintenance and
recycling.

“The alliance focuses on delivering end-to-end solutions by industry, starting
from transformation services to globally restructure product development,” said
Chuck Masur, vice president, DS Global Alliance, IBM. “It is about a long-shared
and well-understood vision of how customers can advance their businesses with
PLM, cutting cycle times and costs, while achieving breakthrough product
innovation with Dassault Systèmes and IBM combined solutions.”

###

About Dassault Systèmes

As a world leader in 3D and Product Lifecycle Management (PLM) solutions,
Dassault Systèmes brings value to more than 115,000 customers in 80 countries. A
pioneer in the 3D software market since 1981, Dassault Systèmes applications
provide a 3D vision of the entire lifecycle of products from conception to
maintenance to recycling. The Dassault Systèmes portfolio consists of CATIA for
designing the virtual product – SolidWorks for 3D mechanical design – DELMIA for
virtual production – SIMULIA for virtual testing – ENOVIA for global
collaborative lifecycle management, and 3DVIA for online 3D lifelike
experiences. For more information, visit http://www.3ds.com.

About IBM

For more information, visit http://www.ibm.com/software/plm

Dassault Systèmes
DS Americas
Derek Lane, +1 818-673-2243
derek.lane@3ds.com
or
DS AP
CJ Lin, +86 21 3856 8039
cj.lin@3ds.com
or
DS EMEA
Arnaud Malherbe, +33 (1) 61 62 87 73
arnaud.malherbe@3ds.com
or
IBM
Lon Levitan, +1 512-286-7216
llevitan@us.ibm.com

Copyright Business Wire 2010

Chicken antibodies may help prevent H5N1 pandemic

Washington, April 20 (ANI): A new research has shown that antibodies in common eggs laid by hens vaccinated against the H5N1 virus can potentially prevent a possible H5N1 pandemic.

According to researchers, their finding raises the possibility that the same principle could be applied to the current H1N1 influenza pandemic.

The research team, led by Dr. Huan Huu Nguyen at the International Vaccine Institute (IVI) and those at the U.S. Centers for Disease Control and Prevention, tested the efficacy of the avian antibodies against both influenza viruses H5N1 and H1N1 in mice.

Chicken antibodies found in egg yolk had been used mainly for treatment of gastrointestinal infections.

“Our tests show proof-of-concept that antibodies, or the antiviral proteins ”immunoglobulins Y (IgY),” found in consumable eggs laid by vaccinated hens may be an affordable, safe, and effective alternative for the control of influenza outbreaks, including the current H1N1 pandemic,” said Dr. Huan Huu Nguyen, an immunologist at the IVI and the lead author of the study.

The researchers isolated H5N1-specific antibodies from consumers” eggs sold in Vietnam, where hens are vaccinated against the pathogen, and tested them against infections with H5N1 and related H5N2 strains in mice.

When delivered into the nose before infection, the antibodies from the egg yolk prevented the infection. When administered after infection, the same antibodies reduced the severity of the infection, enabling mice to recover from the disease.

The chicken antibodies could be administered as a nasal spray. This form of ”passive vaccination” could also be applied to prevent disease caused by the current pandemic H1N1, using egg yolk antibodies from hens vaccinated against the H1N1 virus.

The study was published in the April 13th issue of PLoS ONE. (ANI)

Rexahn Pharmaceuticals Issues Additional Comments and Clarifications on its Phase IIa Study Results of Serdaxin in Major Depressive Disorder (MDD)

ROCKVILLE, Md.–(Business Wire)–
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical
company developing potential best in class oncology and central nervous system
(CNS) therapeutics, today offered additional commentary, clarifications and
insights on yesterday`s announcement of its Phase IIa clinical results of
Serdaxin® in the treatment of major depressive disorder (MDD).

“Based on the feedback and reaction from our shareholders, stakeholders and
other market participants, it is clear that neither the purpose of the Serdaxin
trial or its results were well understood,” said Dr. Chang Ahn, Chief Executive
Officer of Rexahn.

“The purpose of the Serdaxin Phase IIa trial was to establish as a proof of
concept that Serdaxin can work as an antidepressant drug for patients suffering
from Major Depressive Disorder. I am happy to say that this is exactly what the
study accomplished. The trial results unambiguously reach the conclusion that
patients, especially those suffering from severe depression, respond positively
to Serdaxin,” said Dr. Ahn.

The study showed that patients with severe MDD taking 5 mg of Serdaxin (55.6%)
had statistically significant improvement in Montgomery-Asberg Depression Rating
Scale (MADRS) scores after 8 weeks of treatment, compared to placebo (34.0%).

Dr. Ahn added, “Some market participants have asked us why our overall trial
results were not statistically significant. The answer is simply that the
Serdaxin study was never designed to achieve statistical significance as a
primary objective, but rather to establish a positive signal among treated
patients. This is exactly what the trial succeeded in accomplishing.”

“Overall we are extremely pleased with Serdaxin`s Phase IIa results, which
should be viewed as a success. As such, based on the strength of these results
we are now able to move forward with a 300 patient phase IIb clinical trial in
the second half of this year. We believe this study will further substantiate
Serdaxin as a viable treatment for depression,” Dr. Ahn concluded.

About Serdaxin®

Serdaxin® is a potential CNS neuroprotective agent and antidepressant. Rexahn is
currently investigating Serdaxin as a treatment for depression in Phase II
clinical trials. Serdaxin appears to exhibit therapeutic potential and appears
to have no serious side effects such as nausea, vomiting, insomnia, weight gain,
sexual dysfunction, cognitive deficit or motor impairment that are linked to
existing antidepressant drugs. Serdaxin has a well-established, human safety
profile. In preclinical studies, Serdaxin had onset of action in less than two
days. Based on its novel mechanism as a dual serotonin and dopamine enhancer, it
is a potential treatment for multiple CNS disorders where these
neurotransmitters are depleted or implicated in CNS-based illnesses, such as
Parkinson`s disease (PD). Serdaxin has the potential to address both non-motor
and motor events of PD by serving as a neuroprotective agent and addressing loss
of dopaminergic neurons that lead to loss of control of movements; and further,
enhancing serotonin and dopamine levels that are involved in depression and mood
disorders. Rexahn has multiple clinical programs planned for investigating
Serdaxin in the treatment of anxiety disorders, depression, Parkinson`s disease,
Alzheimer`s disease and neurodegenerative illnesses, and biodefense uses.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to
developing best in class therapeutics for cancer, CNS disorders, and sexual
dysfunction. Rexahn currently has three drug candidates in Phase II clinical
trials, Archexin®, Serdaxin®, and Zoraxel – all potential best in class
therapeutics – and a pipeline of preclinical compounds for possible treatment of
cancers and CNS disorders. Rexahn also operates R&D programs of nano-medicines,
3D-GOLD, and TIMES drug discovery platforms. For more information, please visit
www.rexahn.com.

Safe Harbor

This press release contains forward-looking statements, including statements
regarding the planned commencement of a Phase IIb trial in the second half of
2010. Rexahn’s actual results may differ materially from anticipated results,
and expectations expressed in these forward-looking statements, as a result of
certain risks and uncertainties, including Rexahn’s lack of profitability, and
the need for additional capital to operate its business to develop its product
candidates; the risk that Rexahn’s development efforts relating to its product
candidates may not be successful; the possibility of being unable to obtain
regulatory approval of Rexahn’s product candidates; the risk that the results of
clinical trials may not be completed on time or support Rexahn’s claims; demand
for and market acceptance of Rexahn’s drug candidates; Rexahn’s reliance on
third-party researchers and manufacturers to develop its product candidates;
Rexahn’s ability to develop and obtain protection of its intellectual property;
and other risk factors set forth from time to time in the Company`s filings with
the Securities and Exchange Commission, including its Annual Report on Form 10-K
for the year ended December 31, 2009. Rexahn assumes no obligation to update
these forward-looking statements.

Rexahn Pharmaceuticals, Inc.
Investor Relations
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
constantine@basepaircomm.com

Copyright Business Wire 2010

AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program

Milestone Achieved Through Selection of First ErbB3 Antibody Development
Candidate
CAMBRIDGE, Mass.–(Business Wire)–
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on
discovering, developing and commercializing cancer therapeutics, today announced
it has received a $5 million milestone payment from Biogen Idec International
GmbH, a subsidiary of Biogen Idec, Inc. (NASDAQ:BIIB), for the selection of the
first humanized antibody development candidate from its ErbB3 program.

“We are very pleased with the progress we have made on the ErbB3 program and the
selection of the first development candidate,” stated Elan Ezickson, chief
business officer of AVEO. “AVEO has built a state-of-the-art antibody drug
discovery platform dedicated to the delivery of novel, high-quality oncology
antibody drug candidates which has yielded a rich pipeline of product candidates
focused on novel targets of growing interest in oncology such as Notch, RON and
FGFR. The collaboration with Biogen Idec around the ErbB3 program and our
collaboration with Merck on our clinical stage HGF/c-MET product AV-299
represent two of the more than 10 partnerable programs we have generated through
our highly efficient and productive platform.”

In March 2009, AVEO entered into an exclusive option and license agreement with
Biogen Idec International GmbH, a subsidiary of Biogen Idec, regarding the
development and commercialization outside of North America of AVEO`s
discovery-stage ErbB3-targeted antibodies for the potential treatment and
diagnosis of cancer and other diseases. Under terms of the agreement, AVEO is
responsible for developing ErbB3 antibodies through completion of the proof of
concept clinical trial designed to allow dose selection and support generation
of efficacy data that would allow movement to a Phase 3 clinical trial. AVEO
retains the exclusive right to commercialize ErbB3 antibody products in North
America.

About the ErBb3 Program

Through the use of its Human Response Platform, AVEO scientists have highlighted
the importance of the ErbB3 receptor in tumor growth. ErbB3 belongs to a family
of four proteins that also includes EGFR and Her2. Both EGFR and Her2 have been
implicated in promoting the growth of significant numbers of tumors,
particularly in breast and lung cancers. Drugs blocking the activity of EGFR
have demonstrated clinical benefit in lung, colon and head and neck cancers
while drugs targeting Her2 show clinical benefit in the treatment of Her2
over-expressing breast cancers.

ErbB3 is significantly over-expressed in many human breast, ovarian, prostate,
colorectal, pancreatic, gastric, and head and neck cancers and its
over-expression generally correlates with poor prognosis. It has also been
implicated in resistance to certain drugs which target EGFR in lung cancer and
with resistance to radiotherapy. Because ErbB3 preferentially binds with Her2,
AVEO believes that breast cancer patients who do not respond well to anti-Her2
therapy might benefit from drug combinations with an anti-ErbB3 antibody.

Through AVEO`s discovery efforts, the company has identified antibodies that
have been shown to be potent and selective inhibitors of ErbB3 in preclinical
studies. In preclinical testing, these antibodies have significantly inhibited
the growth of a number of different tumors, including breast, prostate and
pancreatic cancers. The company plans to commence manufacturing of this
candidate in preparation for preclinical studies and human clinical trials.

About AVEO

AVEO Pharmaceuticals (NASDAQ:AVEO) blends a proprietary cancer biology platform
with drug development and commercial expertise to discover and develop targeted
cancer therapeutics. The company`s lead product, tivozanib, is an oral, triple
VEGF receptor inhibitor with potential for a best-in-class profile. Tivozanib is
currently being investigated in a global, randomized Phase 3 clinical trial
called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as
well as additional clinical studies in other solid tumor types. AVEO`s
proprietary, integrated cancer biology platform offers the company a unique
advantage in oncology drug development that both increases the probability of
clinical success and provides a discovery engine for high-value targets. This
approach has resulted in a promising pipeline of monoclonal antibodies against
novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information,
please visit the company’s website at www.aveopharma.com.

Any statements in this press release about our future expectations, plans and
prospects, including statements about the expected benefits of our anti-ErbB3
antibody program and our plans to commence manufacturing of the first
development candidate under the collaboration and other statements containing
the words “believes,” “anticipates,” “plans,” “expects,” and similar
expressions, constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of various important factors, including risks relating to: our ability to
successfully research, develop and obtain and maintain regulatory approvals for
our product candidates, including our anti-ErbB3 antibody under development with
Biogen Idec; competitive pressures; our ability to successfully execute on our
strategic plans for future growth; our ability to maintain our strategic
partnerships and risks relating to the failure of our strategic partners to meet
their obligations under their agreements with us; our inability to obtain and
maintain adequate protection for intellectual property rights relating to our
product candidates and technologies; unplanned operating expenses and our
ability to raise substantial additional funds to achieve our goals; general
economic and industry conditions; and other factors discussed in the “Risk
Factors” section of the final prospectus relating to our initial public offering
filed with the Securities and Exchange Commission, and in other filings that we
periodically make with the SEC. In addition, the forward-looking statements
included in this presentation represent our views as of the date of this press
release. We anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim any obligation
to do so. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this press
release.

AVEO Pharmaceuticals, Inc.
David Johnston,Chief Financial Officer, 617-299-5810
or
Pure Communications
Caton Lovett, 910-232-7166

Copyright Business Wire 2010

GeckoSystems Securing Manufacturing for Expansion of Elder Care Robot Trials

CONYERS, GA, Apr 14 (MARKET WIRE) —
GeckoSystems Intl. Corp. (PINKSHEETS: GCKO)
(http://www.geckosystems.com/) — announced today that they will be
performing an on site visit of Sparton Corporation’s Electronic
Manufacturing Services (EMS) in Brooksfield, FL next week. GeckoSystems
is a dynamic leader in the emerging Mobile Service Robot industry
revolutionizing their development and usage with “Mobile Robot Solutions
for Safety, Security and Service(TM).”

Sparton EMS offers a new prototyping service for electronic assemblies
that provides customers several benefits, including time and cost
savings, with increased flexibility. Their service provides a
stand-alone, dedicated pilot line and engineering lab that offers a means
of manufacturing and testing multiple aspects of a customer’s existing or
newly designed electronic assemblies before it is mass produced.
Sparton’s new capabilities are compatible with Proof-of-Concept (PoC)
prototypes, where product design is still evolving, and Production-Ready
(PR) prototypes, where final testing or certifications are the last step
prior to full production.

“Sparton’s new rapid prototyping service offers our customers direct
access to production line equipment, manufacturing engineers, and
manufacturing assets during the design cycle,” said Gene Vigilante,
director, Engineering Services, Sparton Corp. “The prototyping service
doesn’t timeshare with other production lines, but rather allows our
customers access to a fully production-compatible line assembly,
dedicated to PoC and PR prototypes, which significantly increases
probability of first-time design success and shortens the product’s time
to market.”

“After returning from my visit to Sparton Medical in early February of
this year, we realized their focus was on high end medical diagnostic
equipment with relatively small batch sizes. Since we consider Sparton to
be a first tier contract manufacturer, we are now pleased to be visiting
their volume manufacturing facility in FL. Sparton EMS is highly
connected to its Pacific Rim manufacturing plant in Vietnam. With low
cost touch labor available to us in Asia by way of Sparton EMS, we are
very excited about our upcoming review of their facility,” reflected Mark
Peele, Vice President, R&D, GeckoSystems.

“We will be taking our key people on this upcoming trip and demonstrating
a couple of our advanced prototype personal companion robots, the
CareBot(TM) to them. It has been our experience that most electronic
contract manufacturers, after reviewing our bill of materials (BOM) and
seeing a physical prototype, believe they can ramp up to producing 1,000
CareBots per month within four to six months of inception.

“Our ongoing world’s first in home elder care robot trials have been
proceeding since early December with several expected confirmations of
genuine utility and some unexpected family benefits emerging. Given that
we are anticipating pent up demand in the elder care marketplace,
identifying manufacturers with this capability and confidence is of
considerable importance to us.

“We expect our focus on this kind of critical strategic business planning
and execution to increase ROI for our shareholders,” concluded Martin
Spencer, President/CEO, GeckoSystems.

About Sparton Corporation:

Sparton Corporation, now in its 110th year, is a provider of complex and
sophisticated electromechanical devices with capabilities that include
concept development, industrial design, design and manufacturing
engineering, production, distribution, and field service to
technology-driven companies in the medical device, defense & security
systems, and electronic manufacturing services markets. Headquartered in
Schaumburg, Ill., Sparton currently has four manufacturing locations
worldwide. The Company’s Web site may be accessed at

http://www.sparton.com.

About GeckoSystems International Corporation:

Since 1997, GeckoSystems has developed a comprehensive, coherent, and
sufficient suite of hardware and software inventions to enable a new type
of home appliance (a personal robot) the CareBot(TM), to be created for
the mass consumer marketplace. The suite of primary inventions includes:
GeckoNav(TM), GeckoChat(TM) and GeckoTrak(TM).

The primary market for this product is the family for use in eldercare,
care for the chronically ill, and childcare. The primary distribution
channel for this new home appliance is the thousands of independent
personal computer retailers in the U.S. The manufacturing infrastructure
for this new product category of mobile service robots is essentially the
same as the personal computer industry. Several outside contract
manufacturers have been identified and qualified their ability to produce
up to 1,000 CareBots per month within four to six months.

The Company is market driven. At the time of founding, nearly 12 years
ago, the Company did extensive primary market research to determine the
demographic profile of the early adopters of the then proposed product
line. Subsequent to, and based on that original market research, they
have assembled numerous focus groups to evaluate the fit of the CareBot
personal robot into the participant’s lives and their expected usage. The
Company has also frequently employed the Delphi market research
methodology by contacting and interviewing senior executives,
practitioners, and researchers knowledgeable in the area of elder care.
Using this factual basis of internally performed primary and secondary
market research, and third party research is the statistical substance
for the Company’s sales forecasts.

Not surprisingly the scientific statistical analyses applied revealed
that elderly over sixty-five living alone in metropolitan areas with
broadband Internet available and sufficient household incomes to support
the increased costs were identified as those most likely to adopt
initially. Due to the high cost of assisted living, nursing homes, etc.
the payback for a CareBot(TM) is expected to be only six to eight months
while keeping elderly care receivers independent, in their own long time
homes, and living longer due to the comfort and safety of more frequent
attention from their loved ones.

Using U.S. Census Bureau data and various predictive statistical
analyses, the Company projects the available market size in dollars for
cost effective, utilitarian, multitasking eldercare personal robots in
2011 to be $74.0B, in 2012 to be $77B, in 2013 to be $80B, in 2014 to be
$83.3B, and in 2015 to be $86.6B. With market penetrations of 0.03% in
2011, 0.06% in 2012, 0.22% in 2013, 0.53% in 2014, and 0.81% in 2015, we
will anticipate CareBot sales, from this consumer market segment, only,
of $22.0M, $44.0M, $176M, $440.2M, and $704.3M, respectively.

The foregoing forecasts do not include sales in non-metropolitan areas;
elderly couples over 65 (only elderly living alone are in these
forecasts); those chronically ill — regardless of age — or elderly
living with their adult children.

The Company’s “mobile robot solutions for safety, security and
service(TM)” are appropriate not only for the consumer, but also
professional healthcare, commercial security and defense markets.
Professional healthcare require cost effective, timely errand running,
portable telemedicine, etc. Homeland Security requires cost effective
mobile robots to patrol and monitor public venues for weapons and WMD
detection. Military users desire the elimination of the “man in the loop”
to enable unmanned ground and air vehicles to not require constant human
control and/or intervention.

The Company’s business model is very much like that of an automobile
manufacturer. Due to the final assembly, test, and shipping being done
based on geographic and logistic realities; strategic
business-to-business relationships can range from private labeling to
joint manufacturing and distribution to licensing only.

Several dozen patent opportunities exist for the Company due to the many
innovative and cost effective breakthroughs embodied not only in
GeckoNav, GeckoChat, and GeckoTrak, but also in additional, secondary
systems that include: GeckoOrient(TM), GeckoMotorController(TM), the
GeckoTactileShroud(TM), the CompoundedSensorArray(TM), and the
GeckoSPIO(TM).

The present senior management at GeckoSystems has over thirty-five years
experience in consumer electronics sales and marketing and product
development. Senior managers have been identified for the areas of
manufacturing, marketing, sales, and finance.

While GeckoSystems has been in the Development Stage, the Company has
accumulated losses to date in excess of six million dollars. In contrast,
the Japanese government has spent one hundred million dollars in grants
(to Sanyo, Toshiba, Hitachi, Fujitsu, NEC, etc.) over the same time
period to develop personal robots for their eldercare crisis, yet no
viable solutions have been developed.

By the end of this year, the Company plans to complete productization of
its CareBot offering with the introduction of its fourth generation
personal robot, the CareBot 4.0 MSR. The Company expects to be the first
personal robot developer and manufacturer in the world to begin in-home
eldercare evaluation trials.

What Does a CareBot Do for the Care Giver?

The short answer is that it decreases the difficulty and stress for the
caregiver that needs to watch over Grandma, Mom, or other family members
most, if not much, of the time day in and day out due to concerns about
their well being, safety, and security.

But, first let’s look at some other labor saving, automatic home
appliances most of us use routinely. For example, needing to do two or
more necessary chores and/or activities at the same time, like laundering
clothes and preparing supper.

The automatic washing machine needs no human intervention after the dirty
clothes are placed in the washer, the laundry powder poured in, and the
desired wash cycle set. Then, this labor saving appliance runs
automatically until the washed clothes are ready to be placed in another
labor saving home appliance, the automatic clothes dryer. While the
clothes are being washed and/or dried, the caregiver prepares supper
using several time saving home appliances like the microwave oven,
“crock” pot, blender, and conventional stove, with possible convection
oven capabilities.

After supper, the dirty pots, pans, and dishes are placed in the
automatic dishwasher to be washed and dried while the family retires to
the den to watch TV, and/or the kids to do homework. Later, perhaps after
the kids have gone to bed, the caregiver may then have the time to fold,
sort, and put up the now freshly laundered clothes.

So what does a CareBot do for the caregiver? It is a new type of labor
saving, time management automatic home appliance.

For example, the care giver frequently feels time stress when they need
to go shopping for 2 or 3 hours, and are uncomfortable when they have to
be away for more than an hour or so. Time stress is much worse for the
caregiver with a frail elderly parent that must be reminded to take
medications at certain times of the day. How can the caregiver be away
for 3-4 hours when Grandma must take her prescribed medication every 2 or
3 hours? If the caregiver is trapped in traffic for an hour or two beyond
the 2 or 3 they expected to be gone, this “time stress” can be very
difficult for the caregiver to moderate.

Not infrequently, the primary caregiver has a 24 hour, 7 days a week
responsibility. After weeks and weeks of this sometimes tedious, if not
onerous routine, how does the caregiver get a “day off?” To bring in an
outsider is expensive (easily $75-125 per day for just 8 hours) and there
is the concern that medication will be missed or the care receiver have
an accident requiring immediate assistance by the caregiver, or someone
they must designate. And the care receiver may be very resistant to a
“stranger” coming in to her home and “running things.”

So what is it worth for a care receiver to have an automatic system to
help take care of Grandma? Just 3 or 4 days a month “off” on a daylong
shopping trip, a visit with friends, or just take in a movie would cost
$225-500 per month. And that scenario assumes that Grandma is willing to
be taken care of by a “stranger” during those needed and appropriate days
off.

So perhaps, an automatic caregiver, a CareBot, might be pretty handy, and
potentially very cost effective from the primary caregiver’s perspective.

What Does a CareBot Do for the Care Receiver?

It’s a new kind of companion that always stays close to them enabling
family and friends to care for them from afar. It tells them jokes,
retells family anecdotes, reminds them to take medication, reminds them
that family is coming over soon (or not at all), recites Bible verses,
plays favorite songs and/or other music. It alerts them when unexpected
visitors, or intruders are present. It notifies designated caregivers
when a potentially harmful event has occurred, such as a fall, fire in
the home, or simply been not found by the CareBot for too long. It
responds to calls for help and notifies those that the caregiver
determined should be immediately notified when any predetermined adverse
event occurs.

The family can customize the personality of the CareBot. The voice’s
cadence can be fast or slow. The intonation can be breathy, or abrupt.
The voice’s volume can range from very loud to very soft. The response
phrases from the CareBot for recognized words and phrases can be
colloquial and/or unique to the family’s own heritage. The personality
can range from brassy to timid depending on how the care giver, and
others appropriate, chooses it to be.

Generally, the care receiver is pleased at the prospect of family being
able to drop in for a “virtual visit” using the onboard webcam and video
monitor for at home “video conferencing.” The care receiver may feel much
more needed and appreciated when their far flung family and friends can
“look in” on them any where in the world where they can get broadband
internet access and simply chat for a bit.

Why is Grandma really interested in a CareBot? She wants to stay in her
home, or her family’s home, as long as she possibly can. What’s that
worth? Priceless. Or, an average nursing home is $5,000 per month for an
environment that is too often the beginning of a spiral downward in the
care receiver’s health. That’s probably $2-3K more per month for them to
be placed where they really don’t want to be. Financial payback on a
CareBot? Less than a year- Emotional payback for the family to have this
new automatic care giver? Nearly instantaneous-

Safe Harbor:
Statements regarding financial matters in this press
release other than historical facts are “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934, and as that term is defined
in the Private Securities Litigation Reform Act of 1995. The Company
intends that such statements about the Company’s future expectations,
including future revenues and earnings, technology efficacy and all other
forward-looking statements be subject to the Safe Harbors created
thereby. The Company is a development stage firm that continues to be
dependent upon outside capital to sustain its existence. Since these
statements (future operational results and sales) involve risks and
uncertainties and are subject to change at any time, the Company’s actual
results may differ materially from expected results.

Contact:
GeckoSystems

http://www.geckosystems.com/

or
Main number: 1-866-CAREBOT (227-3268)
International: +1 678-413-9236

Copyright 2010, Market Wire, All rights reserved.

Flexible silicon device could help put offbeat hearts back on rhythm

Washington, Mar 25 (ANI): A new type of implantable device for measuring the heart”s electrical output has been created by a team of cardiologists, materials scientists, and bioengineers.

The new device represents the first use of flexible silicon technology for a medical application, say its developers.

“We believe that this technology may herald a new generation of active, flexible, implantable devices for applications in many areas of the body,” says co-senior author Brian Litt, MD, an associate professor of Neurology at the University of Pennsylvania School of Medicine and also an associate professor of Bioengineering in Penn”s School of Engineering and Applied Science. “Initially, we plan to apply our findings to the design of devices for localizing and treating abnormal heart rhythms. We believe these new devices will allow doctors to more quickly, safely, and accurately target and destroy abnormal areas of the heart that are responsible for life-threatening cardiac arrhythmias.

“Implantable silicon-based devices have the potential to serve as tools for mapping and treating epileptic seizures, providing more precise control over deep brain stimulation, as well as other neurological applications,” says Story Landis, PhD, director of the National Institute of Neurological Disorders and Stroke, which provided support for the study. “We are excited by the proof of concept evident in the investigators” ability to map cardiac activity in a large animal model.”

“The new devices bring electronic circuits right to the tissue, rather than having them located remotely, inside a sealed can that is placed elsewhere in the body, such as under the collar bone or in the abdomen,” explains Litt. “This enables the devices to process signals right at the tissues, which allows them to have a much higher number of electrodes for sensing or stimulation than is currently possible in medical devices.”

The team describes their proof-of-principle findings in the cover article of this week”s Science Translational Medicine. (ANI)

Broadband test centre opened

The first three retail service providers for the National Broadband Newtwork in Tasmania have been announced today.

Primus, Internode and iiNet will offer internet access through the Federal Government’s fibre-optic cable network.

The three companies will test their services at a new proof-of-concept centre opened in Hobart today by the Federal Communications Minister, Stephen Conroy.

Senator Conroy says it is an exciting milestone in the delivery of the network to the state.

“This is where all of the new concepts are being tested before they’re delivered in just three months to the Tasmanians who are part of the stage one roll-out,” he said.

“So today’s a very exciting milestone for the Tasmanain National Broadband Network.”

But it is not yet known how much the new internet services will cost consumers – the ISPs are yet to finalise their pricing structures.

Scientists uncover vulnerable enzyme that can be targeted to kill dangerous pathogens

Washington, August 28 (ANI): A collaborative study conducted by researchers from three institutions in the U.S. has shown that an enzyme, which is essential to many bacteria, can be targeted to kill dangerous pathogens.

Experts at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have also identified chemical compounds that can inhibit this enzyme, and suppress the growth of pathogenic bacteria.

Writing about their study in the journal Chemistry and Biology, the researchers say that their findings are essential to develop new broad-spectrum antibacterial agents to overcome multi-drug resistance.

Dr. Andrei Osterman, an associate professor in Burnham’s ioinformatics and Systems Biology program, targeted the acterial nicotinate mononucleotide adenylyltransferase (NadD), an essential enzyme for nicotinamide adenine dinculeotide (NAD) biosynthesis, which has many crucial functions in nearly all important pathogens.

The bacterial NadD differs significantly from the human enzyme.

“It’s clear that because of bacterial resistance, we need new, wide-spectrum antibiotics. This enzyme is indispensable in many pathogens, so finding ways to inhibit it could give us new options against infection,” said Dr. Osterman.

The research team used a structure-based approach to search for low-molecular-weight compounds that would selectively inhibit bacterial NadD, but not the human equivalent, by screening, in silico, more than a million compounds.

In their experiments, they tested the best predicted compounds against Escherichia coli and Bacillus anthracis (anthrax), which led them to a handful of versatile inhibitory chemotypes, which they explored in detail.

Using protein crystallography, a 3D structure of the enzyme in complex with one of the inhibitors was solved providing guidelines for further drug improvement.

“This is proof-of-concept that NadD is a good target to create antibacterial agents. This knowledge will be useful for both biodefense and public health. The next step is to find better inhibitors. We do not have a silver bullet yet, but we are certainly hitting a golden target,” said Dr Osterman.

The research was supported by a grant from the National Institute of Allergy and Infectious Diseases. (ANI)

Scientists uncover vulnerable enzyme that can be targeted to kill dangerous pathogens

Washington, August 28 (ANI): A collaborative study conducted by researchers from three institutions in the U.S. has shown that an enzyme, which is essential to many bacteria, can be targeted to kill dangerous pathogens.

Experts at Burnham Institute for Medical Research (Burnham), University of Texas Southwestern Medical Center and University of Maryland have also identified chemical compounds that can inhibit this enzyme, and suppress the growth of pathogenic bacteria.

Writing about their study in the journal Chemistry and Biology, the researchers say that their findings are essential to develop new broad-spectrum antibacterial agents to overcome multi-drug resistance.

Dr. Andrei Osterman, an associate professor in Burnham’s ioinformatics and Systems Biology program, targeted the acterial nicotinate mononucleotide adenylyltransferase (NadD), an essential enzyme for nicotinamide adenine dinculeotide (NAD) biosynthesis, which has many crucial functions in nearly all important pathogens.

The bacterial NadD differs significantly from the human enzyme.

“It’s clear that because of bacterial resistance, we need new, wide-spectrum antibiotics. This enzyme is indispensable in many pathogens, so finding ways to inhibit it could give us new options against infection,” said Dr. Osterman.

The research team used a structure-based approach to search for low-molecular-weight compounds that would selectively inhibit bacterial NadD, but not the human equivalent, by screening, in silico, more than a million compounds.

In their experiments, they tested the best predicted compounds against Escherichia coli and Bacillus anthracis (anthrax), which led them to a handful of versatile inhibitory chemotypes, which they explored in detail.

Using protein crystallography, a 3D structure of the enzyme in complex with one of the inhibitors was solved providing guidelines for further drug improvement.

“This is proof-of-concept that NadD is a good target to create antibacterial agents. This knowledge will be useful for both biodefense and public health. The next step is to find better inhibitors. We do not have a silver bullet yet, but we are certainly hitting a golden target,” said Dr Osterman.

The research was supported by a grant from the National Institute of Allergy and Infectious Diseases. (ANI)

Scientists report major breakthrough in lithium battery technology

Washington, May 19 (ANI): Scientists have laid the groundwork for a lithium battery that can store and deliver more than three times the power of conventional lithium ion batteries.

Research work into this technology is being done by an NSERC (Natural Sciences and Engineering Research Council of Canada) funded lab at the University Of Waterloo, In Ontario, Canada.

The prospect of lithium-sulphur batteries has tantalized chemists for two decades, and not just because successfully combining the two chemistries delivers much higher energy densities.

Sulphur is cheaper than many other materials currently used in lithium batteries.

It has always showed great promise as the ideal partner for a safe, low cost, long lasting rechargeable battery, exactly the kind of battery needed for energy storage and transportation in a low carbon emission energy economy.

“The difficult challenge was always the cathode, the part of the battery that stores and releases electrons in the charge and recharge cycles,” said professor Linda Nazar of the University of Waterloo.

“To enable a reversible electrochemical reaction at high current rates, the electrically-active sulphur needs to remain in the most intimate contact with a conductor, such as carbon,” she added.

The Canadian research team leap-frogged the performance of other carbon-sulphur combinations by tackling the contact issue at the nanoscale level.

Although they say the same approach could be used with other materials, for their proof of concept study they chose a member of a highly structured and porous carbon family called mesoporous carbon.

At the nanoscale level, this type of carbon has a very uniform pore diameter and pore volume.

Using a nanocasting method, the team assembled a structure of 6.5 nanometre thick carbon rods separated by empty three to four nanometre wide channels.

Carbon microfibres spanning the empty channels kept the voids open and prevented collapse of the architecture.

Filling the tiny voids proved simple.

Sulphur was heated and melted. Once in contact with the carbon, it was drawn or imbibed into the channels by capillary forces, where it solidified and shrunk to form sulphur nanofibres.

Scanning electron microscope sections revealed that all the spaces were uniformly filled with sulphur, exposing an enormous surface area of the active element to carbon and driving the exceptional test results of the new battery.

“This composite material can supply up to nearly 80 percent of the theoretical capacity of sulphur, which is three times the energy density of lithium transition metal oxide cathodes, at reasonable rates with good cycling stability,” said Dr. Nazar. (ANI)

Genetic secrets of date palm unlocked

Washington, May 2 (ANI): By mapping a draft version of the date palm genome, scientists at Weill Cornell Medical College in Qatar (WCMC-Q) have unraveled the genetic secrets stored in the fruit.

Date palm trees play a significant role in agriculture throughout the Middle East, Northern Africa and Pakistan and the fruit is a major source of nutrition in those areas.

Joel Malek, director of the Genomics Laboratory at Weill Cornell Medical College in Qatar, said that the date palm sequencing work was a proof-of-concept study.

“We have generated a draft DNA sequence and initial assembly of the date palm using the most advanced technology,” said Malek.

Genetic information about the date palm is extremely valuable to researchers who are working to improve fruit yield and quality and to better understand susceptibility and resistance to disease.

“This is an important step for our biomedical research program. It clearly demonstrates the feasibility and success of the most advanced genomics technologies in Qatar and represents a milestone toward establishing Qatar and Weill Cornell as a regional research center of excellence.

In addition, this achievement by the WCMC-Q research team holds great promise for the application of the genomics technology to a better understanding of biomedical problems,” said Khaled Machaca, Ph.D., professor of physiology and biophysics.

To produce the draft map, researchers used a next-generation sequencing approach, which, according to Malek, offers data quality between that of the expressed sequence tag (EST) method and the traditional whole-genome mapping method.

“We were able to develop a relatively unbiased view of the gene space of the entire date palm plant at a fraction of the cost and in a much shorter period of time. Using this approach, which takes advantage of the lower repetitive DNA in the date palm gene regions, we have increased the publicly available knowledge of the date palm gene by about 1,000 fold,’ said Malek.

The researchers obtained the DNA from leaves of the date palm provided by the Qatar Plant Tissue Culture Lab in the Department of Agriculture and Water Research (Qatar Ministry of Municipal Affairs and Agriculture).

Malek said that his team would continue to improve the draft sequence and publish their data. (ANI)

Gene that suppresses skin cancer growth identified

London, March 30 (ANI): Scientists at the National Institutes of Health (NIH) in the U.S. have announced the discovery of a gene that suppresses tumour growth in melanoma, the deadliest form of skin cancer.

The finding was made as part of a systematic genetic analysis of a group of enzymes implicated in skin cancer, and many other types of cancer.

According to the analysis, one-quarter of human skin cancer tumours had mutations in genes that code for matrix metalloproteinase (MMP) enzymes.

The researchers believe that their findings may pave the way for more individualized cancer treatment strategies, where MMP and other key enzymes play a functional role in tumour growth and spread of the disease.

They even say that their study may help understand why drugs designed to treat cancer by blocking MMP enzymes have not been very successful as yet.

During the current study, the team led by researchers from the National Human Genome Research Institute (NHGRI) have found that MMP-8 actually serves as a tumour suppressor gene in melanoma, which is why may not be wise to block all MMPs in skin cancer patients with mutation in this gene.

The researchers say that a better approach may be to look for drugs that restore or increase MMP-8 function, or for drugs that block only those MMPs that are truly oncogenes-genes that encode proteins involved in normal cell growth.

“This research is an illustrative proof of concept that shows the value of genomic strategies for understanding cancer and possible therapies,” Nature magazine quoted Dr. Eric Green, NHGRI Scientific Director, as saying.

“It is gratifying to see that genomic technologies are guiding scientific discovery, advancing cancer research, especially melanoma research,” Green added.

While experimenting on mice, the researcher observed that when they injected the animals with cells expressing normal MMP-8, they would not develop skin ulcers.

However, when the mice were injected with cells expressing mutated MMP-8, they went on to develop ulcerations and metastases in their lungs.

A research article on the gene discovery has been published in the journal Nature Genetics. (ANI)

Malaria treatment developed using synthetic biology, fermentation

Washington, Feb 28 (ANI): Achieving a milestone in the fight against malaria, scientists at Amyris Biotechnologies have produced 25 g/L of amorphadiene, a precursor of the antimalarial agent artemisinin, by using synthetic biology and E. coli fermentations.

It was in 2003 that the production of amorphadiene in E. coli was first described, but the amount produced was low (50 mg/L). The level was increased to 0.5g/L in 2006, but still 50-fold lower than target production levels.

In the new study, researchers have described the interplay of industrial fermentation processes and synthetic biology that achieve the required 50-fold increase in production levels.

This milestone acts as proof of concept that microbes for conversion to artemisinin can produce commercially relevant concentrations of artemisinin precursors.

The World Health Organization considers artemisinin-based combination therapies (ACTs) to be first-line treatment for malaria.

But, as the supplies of plant-derived artemisinin are subject to the seasonality and volatility common to many plant-based commodities, it leads to fluctuations in the price of artemisinin.

Commercial scale production of semi-synthetic artemisinin would have the potential to stabilize supply and supplement existing plant-derived materials to create a consistent, high-quality and affordable new source of artemisinin to help meet the projected world-wide demand for ACTs.

Originally, the microbial production of Artemisinin precursors was demonstrated in the lab of Professor Jay Keasling at the University of California, Berkeley.

Then Keasling continued the research and founded Amyris to bring the technology to the developing world.

Dr. Jack Newman, a former Post-doc in the Keasling lab and co-founder of Amyris, praised the collaboration effort and the potential of the technology.

“The enormous amount of work involved on the road from idea through execution is mind-boggling. I’m grateful to the dedicated team of researchers, philanthropists and visionaries that made this happen. They have demonstrated the potential of this technology to make a difference in the world,” he said

The article, “High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli” appears in PLoS ONE, an open-access journal from the Public Library of Science. (ANI)